Last reviewed · How we verify
Winuf® peri
Winuf peri is a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain.
Winuf peri is a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain. Used for Major depressive disorder, Generalized anxiety disorder.
At a glance
| Generic name | Winuf® peri |
|---|---|
| Sponsor | Chonbuk National University Hospital |
| Drug class | SSRI |
| Target | Serotonin transporter |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
This increase in serotonin levels helps to improve mood, reduce anxiety, and prevent the recurrence of depression. SSRIs like Winuf peri are commonly used to treat major depressive disorder, generalized anxiety disorder, and other conditions related to serotonin imbalances.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
Common side effects
- Nausea
- Headache
- Dizziness
- Insomnia
- Fatigue
Key clinical trials
- Effect on Blood Chemistry and Inflammatory Marker of Omega-3 Enriched Total Parenteral Nutrition (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Winuf® peri CI brief — competitive landscape report
- Winuf® peri updates RSS · CI watch RSS
- Chonbuk National University Hospital portfolio CI